Results 1 to 10 of about 6,788,512 (239)

Longitudinal relationships between disability and gait characteristics in people with MS

Scientific Reports, 2022
Longitudinal data are vital in order to understand intra individual gait changes with the progression of multiple sclerosis (MS). Therefore, the primary aim of this study was to explore the relationship between changes in disability with changes in major
Sapir Dreyer-Alster, Shay Menascu, Mark Dolev, Uri Givon, David Magalashvili, Anat Achiron, Alon Kalron   +6 more
doaj   +1 more source

Targeted cognitive game training enhances cognitive performance in multiple sclerosis patients treated with interferon beta 1-a

Journal of NeuroEngineering and Rehabilitation, 2021
Background Prevention of cognitive decline in Multiple Sclerosis (MS) is of major importance. We explored the effect of a 6 months computerized game training program on cognitive performance in MS patients with mild cognitive impairment. Methods This was
Shay Menascu, Roy Aloni, Mark Dolev, David Magalashvili, Keren Gutman, Sapir Dreyer-Alster, Franck Tarpin-Bernard, Ran Achiron, Gil Harari, Anat Achiron   +9 more
doaj   +1 more source

The MULTI-ACT model: the path forward for participatory and anticipatory governance in health research and care

Health Research Policy and Systems, 2022
The COVID-19 pandemic has unmasked even more clearly the need for research and care to form a unique and interdependent ecosystem, a concept which has emerged in recent years.
Paola Zaratin, Deborah Bertorello, Roberta Guglielmino, Danilo Devigili, Giampaolo Brichetto, Valentina Tageo, Gabriele Dati, Stephanie Kramer, Mario Alberto Battaglia, Monica Di Luca   +9 more
doaj   +1 more source

Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis

Brain : a journal of neurology, 2023
Multiple sclerosis is a complex autoimmune disease, and several therapies for multiple sclerosis have been developed and widely used. However, existing medications for multiple sclerosis were far from satisfactory due to their failure to suppress ...
Jianfeng Lin, Jiawei Zhou, Yan Xu
semanticscholar   +1 more source

Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition

Multiple Sclerosis, 2020
Background: High-quality epidemiologic data worldwide are needed to improve our understanding of disease risk, support health policy to meet the diverse needs of people with multiple sclerosis (MS) and support advocacy efforts.
C. Walton, Rachel King, Lindsay Rechtman, W. Kaye, E. Leray, R. Marrie, N. Robertson, N. La Rocca, B. Uitdehaag, I. A. van der Mei, M. Wallin, A. Helme, Ceri Angood Napier, N. Rijke, P. Baneke   +14 more
semanticscholar   +1 more source

Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study.

Lancet Neurology, 2022
BACKGROUND Serum neurofilament light chain (sNfL) is a biomarker of neuronal damage that is used not only to monitor disease activity and response to drugs and to prognosticate disease course in people with multiple sclerosis on the group level.
P. Benkert, S. Meier, S. Schaedelin, A. Manouchehrinia, Ö. Yaldizli, A. Maceski, J. Oechtering, L. Achtnichts, D. Conen, T. Derfuss, P. Lalive, C. Mueller, S. Müller, Y. Naegelin, J. Oksenberg, C. Pot, A. Salmen, E. Willemse, I. Kockum, K. Blennow, H. Zetterberg, C. Gobbi, L. Kappos, H. Wiendl, Klaus Berger, M. Sormani, C. Granziera, F. Piehl, D. Leppert, J. Kuhle   +29 more
semanticscholar   +1 more source

Multiple sclerosis progression: time for a new mechanism-driven framework.

Lancet Neurology, 2022
Traditionally, multiple sclerosis has been categorised by distinct clinical descriptors-relapsing-remitting, secondary progressive, and primary progressive-for patient care, research, and regulatory approval of medications. Accumulating evidence suggests
T. Kuhlmann, M. Moccia, Timothy Coetzee, Jeffrey A. Cohen, J. Correale, J. Graves, R. Marrie, X. Montalban, V. W. Yong, A. Thompson, D. Reich, M. Amato, B. Banwell, F. Barkhof, J. Chataway, T. Chitnis, G. Comi, T. Derfuss, M. Finlayson, M. Goldman, Ari J. Green, K. Hellwig, D. Kos, Aaron E Miller, E. Mowry, Jiwon Oh, A. Salter, M. Sormani, M. Tintoré, H. Tremlett, M. Trojano, A. van der Walt, S. Vukusic, E. Waubant   +33 more
semanticscholar   +1 more source

Epstein–Barr virus and multiple sclerosis

Nature Reviews Microbiology, 2022
Epstein–Barr virus (EBV) is a ubiquitous human lymphotropic herpesvirus with a well-established causal role in several cancers. Recent studies have provided compelling epidemiological and mechanistic evidence for a causal role of EBV in multiple ...
S. Soldan, P. Lieberman
semanticscholar   +1 more source

Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

Annals of Neurology, 2021
This study was undertaken to assess the impact of immunosuppressive and immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID‐19) in people with multiple sclerosis (PwMS).
M. Sormani, N. De Rossi, I. Schiavetti, L. Carmisciano, C. Cordioli, L. Moiola, M. Radaelli, P. Immovilli, M. Capobianco, M. Trojano, P. Zaratin, G. Tedeschi, G. Comi, M. Battaglia, F. Patti, M. Salvetti   +15 more
semanticscholar   +1 more source

Cognitive rehabilitation in multiple sclerosis: Three digital ingredients to address current and future priorities

Frontiers in Human Neuroscience, 2023
Multiple sclerosis (MS) is a neurological chronic disease with autoimmune demyelinating lesions and one of the most common disability causes in young adults.
Andrea Tacchino, Jessica Podda, Valeria Bergamaschi, Ludovico Pedullà, Giampaolo Brichetto, Giampaolo Brichetto   +5 more
doaj   +1 more source